Lykos Therapeutics' goal is to revolutionize the way mental health is addressed. By creating innovative medicines and therapeutic techniques to treat mental health disorders, we hope to upend the status quo. With over thirty years of expertise investigating therapies aided by psychedelics, we continue to be committed to adhering to rigorous science so that we can create and market innovative treatment alternatives.
MAPS renames to Lykos Therapeutics; raises USD 100 million in Series A funding
Psychedelic Medicine
Partnerships
Jun 15, 2023
Numinus partners with MAPS to offer psychedelic experiential opportunities for practitioners
Psychedelic Medicine
Partnerships
Jan 19, 2022
Awakn Life Sciences to partner with MAPS to explore MDMA therapy
Psychedelic Medicine
Partnerships
Sep 14, 2021
Wesana Health collaborates with MAPS with initial investment of USD 1.5 million
Psychedelic Medicine
Industry news
May 3, 2021
MDMA therapy on track for FDA approval with promising Phase 3 clinical trial results
Psychedelic Medicine
Click here to learn more
Get a demo
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.